Canadian researchers believe that a diet program involving FDA-recognized heart-healthy foods may be more effective at lowering LDL cholesterol than a low-saturated fat diet.
Canadian researchers believe that a diet program involving FDA-recognized heart-healthy foods may be more effective at lowering low-density lipoprotein (LDL) cholesterol than a low-saturated fat diet.
In a multi-center trial, the researchers assigned 351 hyperlipidemic adults to one of three dietary programs for six months: a control diet or an intervention diet containing heart-healthy food components, with dietician visits on two occasions (“routine”) or seven occasions (“intensive”). Changes in LDL cholesterol were measured over the course of the study.
The control diet emphasized low-fat dairy, whole grain cereals, fruits, vegetables, and avoidance of heart-healthy foods from the intervention diets.
Per 1000 kcal, the intervention diet aimed for 0.94 g of plant sterols, 9.8 g of viscous fibers (from oats, barley, and psyllium), 22.5 g of soy protein, and 22.5 g of nuts. Consumption of peas, beans, and lentil was encouraged.
“The specific food components used in the portfolio have well-established cholesterol-lowering properties and are recognized by the U.S. FDA as justifying a heart health claim,” wrote lead researcher David Jenkins, MD, of St. Michael’s Hospital (Toronto). “Review articles and meta-analyses have confirmed [LDL-cholesterol] benefits for viscous fibers, plant sterols, soy proteins, and nuts.”
By six months, participants in the control group had experienced a 3.0% decrease in LDL cholesterol. But participants in the intervention groups experienced significant reductions of 13.8% and 13.1% with the intensive and routine regimens, respectively.
With just two clinical visits and a food-specific dieting program, the researchers concluded that such a strategy might be suitable as a clinical approach.
Study limitations included a high drop-out rate of 22.6%, predominantly white participants, and participants who were considered to be at low to intermediate risk of cardiovascular disease. The effect of this type of dietary intervention on high-risk, obese subjects remains to be seen.
Funding and support for the study was provided by the Canada Research Chair Endowment of the Federal Government of Canada, the Canadian Institutes of Health Research, Advanced Foods and Materials Network (Guelph, ON), Loblaw Brands Ltd. (Brampton, ON), Solae (St. Louis, MO), and Unilever (Vlaardingen, the Netherlands, and Toronto, ON).
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.